BMJ Open Assessing healthcare workers' confidence level in diagnosing and managing emerging infectious virus of <section-header><section-header> Auman mpox in hospitals in Amhara Begion, Northwest Ethiopia: multicentro Auman factor of the sector of human mpox in hospitals in Amhara

To cite: Yeshiwas AG, Temesegen A, Melkie G, et al. Assessing healthcare workers' confidence level in diagnosing and managing emerging infectious virus of human mpox in hospitals in Amhara Region, Northwest Ethiopia: multicentre institution-based crosssectional study. BMJ Open 2024;14:e080791. doi:10.1136/ bmjopen-2023-080791

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2023-080791).

AGY and GM contributed equally.

Received 24 October 2023 Accepted 10 June 2024

Check for updates

C Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BM.J.

For numbered affiliations see end of article.

Correspondence to

Almaw Genet Yeshiwas; yeshiwas690@gmail.com

confidence level in diagnosing and managing mpox disease was found to be 31.5% (95% CI: 27.9%, 35.2%). Similarly, 26.8% (95% CI: 23.2%, 30.3%) and 41.8% (95% CI: 38.1%, 45.4%) of HCWs expressed medium and low confidence level to diagnose and manage the disease, respectively. The odds of higher confidence versus lower or medium confidence level in diagnosing and managing mpox were greater for HCWs who regularly visit amenable websites (adjusted OR (AOR)=1.59, 95% CI: 1.16, 2.2), were physicians (AOR=1.9, 95% CI: 1.32, 2.73), were aged 30-35 years old (AOR=1.64, 95% CI: 1.12, 2.39), had got public health emergency epidemic disease management training (AOR=2.8, 95% CI: 1.94, 4.04) and had positive attitudes (AOR=1.72, 95% CI: 1.26, 2.36) compared with their counterparts.

Conclusion The overall confidence level of HCWs in diagnosing and managing mpox disease in the study area was low. Therefore, the HCWs should be regularly updated

a double-stranded DNA virus belonging to the genus Orthopoxvirus within the Poxviridae family, almost similar to variola virus respon-sible for smallpox.¹² The mpox disease is orig-inally a viral zoonotic infection that spreads family, almost similar to variola virus responfrom animals to humans. However, human-tohuman and environment-to-human transmissions were also evident recently.³⁴ The genetic changes of the virus over time enhanced its ability to infect different species and adapt to new environments. Furthermore, the zoonotic spillover of mpox has also provided the virus to jump from animals to humans and raised concerns about the potential for increased virulence or the emergence of more transmissible strains in the future.⁵

l simi

BMJ

The mpox virus was first isolated from monkeys in laboratories in Copenhagen, Denmark in 1958⁶⁷ and the first human case, a 9-month-old patient, was identified in Democratic Republic of Congo (DRC) in 1970.⁸ The first mpox outbreak outside Africa was documented in the USA in 2003, which originated from an infected rodent species imported from West Africa.⁹ Since then, there was sporadic occurrence of mpox outbreaks in endemic regions in Africa. The problem is particularly severe in the DRC, the country where a survey research revealed that of 77 suspected cases that spread across 138 homes, 27.3% of PCR tests were positive for mpox, with the largest recorded number of cases (882) and deaths (2) documented.¹⁰ Moreover, the Nigerian mpox outbreak in 2017 leads to the spread of the disease to the UK and elsewhere in Europe, followed by a dramatic increase in the number of mpox infections. Consequently, we now face a period of multiple outbreaks in countries without clear epidemiological links to endemic countries.^{11 12}

As of 30 December 2023, approximately 92 783 confirmed cases and 660 probable cases, including 171 deaths, have been reported across 116 countries since 1 January 2022. Notably, nearly 98% of cases and 88% of deaths were reported from countries that have not historically reported mpox.^{13 14} The case fatality ratio of mpox is lower than that of smallpox,¹⁵ as its case fatality reaches 17%, which is well below that of smallpox (25-40%).¹⁶

The mpox disease is primarily a cutaneous illness with lymphadenopathy. It is transmitted through direct or indirect close contact with droplets, fomites, skin lesions or contaminated body fluids.¹⁷⁻²² Additionally, it can be transmitted through sexual intercourse and motherto-fetus transmission.^{23 24} The mpox disease is also selflimiting, with symptoms ranging from mild to severe. These symptoms include itchy to painful skin lesions, fever, generalised headache, fatigue, lymphadenopathy, back pain and myalgia.²²⁻²⁴ The symptoms of mpox normally disappear after 14-21 days, following an incubation period of 5–21 days.^{22 25} The most prominent clinical symptom of mpox is a skin rash that typically appears up to 3 days after fever. However, in more severe cases, this rash can be observed throughout the body.^{26 27} Patients admitted to the hospital show clinical manifestations of complications such as bacterial superinfection, dehydration and respiratory distress.^{19 28}

Several risk factors are linked to an increase in mpox outbreaks, including the interruption of smallpox vaccination, which leads to increased susceptibility to mpox infection; the extensive consumption of animals as a protein source, which are potential mpox virus reservoirs; increased population density; ease of travel; and ecological and environmental factors, such as clearing of tropical rainforests with an increased risk of exposure to reservoir animals.^{29–33}

Enhancing case definition, epidemiological, clinical, genomic and molecular surveillance alone is not enough to prevent the mpox epidemic. Instead, it requires integrated health promotion or education, as well as

<page-header><text><text><text><text><text><text>



Figure 1 Map of the Amhara Region where hospitals of the healthcare workers included were located. The healthcare workers were selected to assess their confidence level of the mpox disease (Northwest Ethiopia, 2022).

Source and study population

All HCWs working in public hospitals in the Amhara Region were taken as the source population, and those HCWs working in randomly selected public hospitals were considered as the study population.

Inclusion and exclusion criteria

All HCWs working in public hospitals in the Amhara Region were included in this study; however, those HCWs who are not available during data collection and who are on annual/maternal leave were excluded from the study.

Patient and public involvement

There is no involvement of patients and/or the HCWs in the design, or conduct, or reporting or dissemination plans of this research.

Sample size determination

The minimum sample size that represents the source population was estimated considering the single population proportion formula with the following assumptions: 95% CI, power (β =80%), proportion of HCWs assessed for their confidence level in diagnosing and managing patients with mpox (p=50%), considering no previous study in Ethiopia,⁴² standard normal distribution ($Z_{a/2}$ =1.96), margin of error (d=5%) and design effect (1.5). Therefore, the final adequate sample size including 10% non-response rate was 640 HCWs.

Sampling procedure and technique

A multistage stratified random sampling was employed to select HCWs working in hospitals in the Amhara Region. 28 hospitals (9 from general and comprehensive specialised hospitals and 19 from primary hospitals), representing 28.6% of the total hospitals in the region, were selected randomly. The sample size was proportionally allocated to each selected hospital and similarly to each professional stratification. Finally, the HCWs who provided their responses in the data collection were selected using simple random sampling.

Variables

The dependent variable was HCWs' confidence level in diagnosing and managing mpox disease (categorised as poor, medium or high confidence). The independent variables included the sociodemographic characteristics such as age, residence, marital status and level of education; professional category and years of experience. The independent variables also included some personal behaviours such as the knowledge and attitude towards mpox disease, previous training exposure on public health emergency epidemic disease management (PHEM), habit of regular participation in the morning session and the habit of visiting websites of the WHO, Center for Disease Control and Prevention (CDC) and other websites.

Operational definitions

HCWs' confidence level

A total of 44 questions (9 related to preparedness, 28 related to diagnoses, 7 related to management of mpox disease) were used to measure HCWs' confidence level. Each question had three responses: 'yes' coded as +1, 'no' coded as 0 and 'I do not know' coded as -1. The responses from each respondent were summed and the percentage score of $\geq 80\%$ was labelled as higher confidence, 50–79% labelled as medium confidence and <50% labelled as poor confidence level.^{43 44}

Knowledge

The knowledge score was calculated from 35 questions (28 related to diagnosis and 7 related to management of mpox disease) with three responses: 'yes' coded as +1, 'no' coded as 0 and 'I do not know' coded as -1. The percentage of knowledge score for each respondent was categorised into three labels: <50% was labelled as less knowledgeable, 50-79% was labelled as moderately knowledgeable and $\geq 80\%$ was labelled as knowledgeable.^{18 44}

Attitude

The HCWs' attitude was assessed using a 7-point Likert scale with 14 questions (strongly disagree (1), disagree (2), somewhat disagree (3), neutral/no opinion (4), somewhat agree (5), agree (6) and strongly agree (7)). The sum of their responses was calculated as attitude score between 14 and 98. Those HCWs who scored less than 70% were considered to have negative attitude and those who scored \geq 70% were considered to have positive attitude.43

Validity and reliability of the questionnaire

The tool's validity and reliability were also assessed. The degree to which all items in the questionnaire reflect the

tected

contents to which the instrument will be generalised was assessed using reliability and validity tests. Five general practitioners (GPs) reviewed the questionnaires. The content validity ratio (CVR) formula, CVR=(Ne-n/2)/ (n/2), was used to determine whether the questionnaires were relevant, needed revision or should be removed.45 The CVR scores of diagnosis, management and preparedness questionnaires were 0.952, 1.00 and 0.963, respectively. On the other hand, the CVR scores for knowledge, attitude and confidence level were 0.9619, 0.8815 and T 0.9619, respectively (online supplemental files 1 and 2). The instrument has an overall Cronbach's alpha coefficient value of 0.846, which is used to evaluate the questionnaire's consistency across all items.

Data collection tools and procedure

by copyright, Data were collected using a structured questionnaire, which was prepared after reviewing previous studies conducted for similar purposes.46-50 The questionnaire was developed in English, then translated into Amharic (local language), then back to English to ensure its consistency. The questionnaire contained sociodemographic characteristics and habit-related factors of the graphic characteristics and habit-related factors of the HCWs. Data collection was conducted using KoboCollect (V.2022.4.4). 29 GPs and 5 master's holder health professionals were recruited to manage the data collection sionals were recruited to manage the data collection process.

Data quality assurance

Data quality was assured using a properly designed questionnaire adapted from literature. Two-day training was provided for both data collectors and supervisors in the purpose of the study, data collection techniques and tools $\mathbf{\bar{a}}$ conducted by the principal investigators. The data collectors pretested the questionnaires, on 5% of the sample size at Injibara Health Center where the study was not ≥ undertaken, and necessary amendments were taken based on the findings of the pretest. Every day after data uning, collection, the principal investigator reviewed the questionnaires to ensure the completeness of each response. and The principal investigator and supervisor closely monitored the data collection process. similar

Data management and analysis

Data were exported to STATA V.17 from the Kobo-Collect data collection toolbox. Data were cleaned (categorisation for continuous variables and recategorisation for categorical variables) and descriptive & statistics such as frequency distribution tables, means **g** and SDs were computed to describe the data. Bivariate and multivariable ordinal logistic regression analyses were used to identify predictors of HCWs' confidence level in diagnosing and managing mpox disease. The proportional odds assumption was checked (X^2 p value=0.054) to evaluate whether the distance between each category of the outcome was equivalent or not. The two cut-off points, cut1=0.8603 and cut2=2.083, were estimated to see the inherently ordered distances

between low, medium and high confidence level in diagnosing and managing mpox disease. A p value of <0.25 was used as a criterion during bivariate analysis to retain variables for the multivariable ordinal logistic regression model. Crude and adjusted ORs (AORs) with 95% CI were calculated to measure the degree of association between independent variables and HCWs' confidence level in diagnosing and managing mpox disease. A p value of <0.05 was considered as a level of statistical significance in multivariable ordinal logistic regression analysis.

RESULTS

Sociodemographic characteristics of HCWs

620 HCWs (with a response rate of 96.9%) gave a complete response. The majority (312 (50.3%)) of HCWs were Orthodox Christian followers. Similarly, 63.9% of the HCWs had more than 5 years of experience. The mean (\pm SD) age of the HCWs was 31.67 (± 5.355) years old and 432 (69.7%) of them were male. Only 153 (24.7%) HCWs had gotten PHEM from governmental and non-governmental organisations (table 1).

HCWs' confidence level in diagnosing and managing mpox

The overall proportion of HCWs who had high confidence level in diagnosing and managing mpox disease was found to be 31.5% (95% CI: 27.9%, 35.2%). Similarly, 26.8% (95% CI: 23.2%, 30.3%) and 41.8% (95% CI: 38.1%, 45.4%) of HCWs expressed medium and low confidence level in their ability to diagnose and manage mpox disease, respectively. Aside from that, 22.1% (95% CI: 19.0%, 25.5%) of HCWs had higher confidence level in diagnosing and 20.2% (95% CI: 17.2%, 23.4%) of them had higher confidence level in managing mpox disease (figure 2).

HCWs' knowledge and attitude towards mpox

Although about 41.7% (95% CI: 37.9%, 45.8%) of HCWs were less knowledgeable, more than half (361 (58.2%)) of them responded that the mpox virus is prevented by frequent handwashing for at least 20 s with soap and water or alcohol. Similarly, more than half (328 (52.9%)) of them responded that antibiotics can be used to treat mpox disease. However, only 36.9% of HCWs had knowledge on contaminated environment-to-person transmissions of mpox and 34.3% of them responded that mpox is a bacterial disease. About 44.4% of physicians and only 27.6% of nurses and other professionals had higher knowledge about mpox (figure 3).

Regarding HCWs' attitude towards mpox, only 35.8% (95% CI: 32.3%, 39.6%) of them had positive attitude, leaving the majority (64.2% (95% CI: 60.4%, 67.7%)) of the HCWs with negative attitude. A higher percentage (42.3%) of physicians had positive attitude towards mpox virus compared with nurses and other professionals (33.9%) (figure 3).

Factors associated with HCWs' confidence level in diagnosing and managing mpox disease

In binary ordinal logistic regression analysis, variables such as working hospital standards, sex, work experience, occupational category, regular participation in morning sessions, exposure to PHEM training, attitude, visiting WHO, CDC and other websites, and age group were selected as candidates for multivariable ordinal logistic regression analysis. During the multivariable ordinal logistic regression analysis, variables such as positive attitude, aged 30–35 years old, professional category and habit of visiting the WHO, CDC and other amenable websites were found to be significantly associated with the outcome variable.

copyri The HCWs with a cut-off point value of ≤13.97% were classified as having a low confidence level, given that they igh were working in a primary hospital, female, have <5 years of work experience, a nurse and other health professionals, not participating in a morning session, not receiving PHEM training, having a negative attitude, not visiting the WHO, CDC and other websites, and aged <30 years old as opposed to between 30 and 35 years. Similarly, the 5 HCWs with a cut-off point value of ≥2.083 were classified as having a higher confidence level, given that the above variables were kept similar with their reference. Additionſe ally, participants with a cut-off point value between 0.8603 and 2.083 were considered to have medium confidence to text level where the independent variables were kept similar with their reference.

The odds of higher confidence level versus lower or a medium confidence level in diagnosing and managing mpox disease were 1.59 times (AOR=1.596, 95% CI: 1.158, 2.198) higher for the HCWs who regularly visit the WHO, CDC and other potential websites than those who do not visit the websites when other variables were kept constant. The odds of higher confidence versus > lower or medium confidence level were 1.9 times (AOR=1.899, 95% CI: 1.318, 2.734) higher for physicians in comparison with nurses and other professionals when the other variables are kept constant. Similarly, the odds of higher versus lower or medium confidence level in managing and diagnosing mpox disease were 1.6 (AOR=1.637, 95% CI: 1.118, 2.397) times greater for HCWs if their age is 30-35 years compared with less than 30 years old when the other variables were kept constant.

Moreover, the odds of higher versus lower or medium confidence level in managing and diagnosing mpox disease were 2.8 times (AOR=2.799, 95% CI: 1.942, 4.035) greater for HCWs who had exposure to PHEM training than their counterparts. Lastly, the odds of higher confidence level versus lower or medium confidence level in managing and diagnosing mpox disease were 1.72 times (AOR=1.724, 95% CI: 1.258, 2.362) greater for HCWs who had positive attitudes than their counterparts when the other variables were kept constant (table 2).

| | Confidence level of HCWs | | | | |
|---|--------------------------|-------------------|-----------------|----------------|---------|
| Characteristics | Low confidence | Medium confidence | High confidence | X ² | P value |
| Religion of HCW | | | | | |
| Orthodox | 136 | 79 | 97 | 4.047 | 0.670 |
| Muslim | 70 | 49 | 52 | | |
| Protestant | 36 | 30 | 29 | | |
| Others* | 17 | 8 | 17 | | |
| Visits WHO, CDC and other amenable websites | | | | | |
| No | 189 | 104 | 121 | 7.718 | 0.021 |
| Yes | 70 | 62 | 74 | | |
| Occupational category | | | | | |
| Physician | 50 | 29 | 63 | 14.442 | 0.001 |
| Nurse and others† | 209 | 137 | 132 | | |
| Year of experience | | | | | |
| <5 | 100 | 57 | 67 | 1.187 | 0.553 |
| >5 | 159 | 109 | 128 | | |
| Hospital where HCW works | | | | | |
| CSPH | 177 | 108 | 132 | 0.518 | 0.772 |
| Primary hospital | 82 | 58 | 63 | | |
| Sex | | | | | |
| Male | 179 | 118 | 140 | 0.424 | 0.809 |
| Female | 80 | 48 | 55 | | |
| Participates in morning sessions | | | | | |
| No | 142 | 74 | 96 | 4.385 | 0.112 |
| Yes | 117 | 92 | 99 | | |
| PHEM training | | | | | |
| No | 215 | 135 | 117 | 36.086 | 0.001 |
| Yes | 44 | 31 | 78 | | |
| Age of HCW | | | | | |
| <30 years | 142 | 86 | 83 | 9.691 | 0.046 |
| 30–35 years | 49 | 38 | 59 | | |
| >35 years | 68 | 42 | 53 | | |
| Highest level of formal education | | | | | |
| Diploma | 22 | 20 | 21 | 5.923 | 0.432 |
| Degree | 184 | 119 | 126 | | |
| Master (MPH/MSC) | 30 | 13 | 24 | | |
| Specialist | 23 | 14 | 24 | | |
| HCW's profession | | | | | |
| Pharmacist | 26 | 12 | 12 | 40.79 | 0.197 |
| Nurse | 86 | 66 | 55 | | |
| Health officer | 20 | 16 | 11 | | |
| Midwife | 40 | 22 | 26 | | |
| General practitioner | 23 | 19 | 29 | | |
| l aboratory professional | 15 | 11 | 7 | | |

Table 1 Continued

| | Confidence level of HCWs | | | | | |
|-----------------------------------|--------------------------|-------------------|-----------------|-----------------------|---------|--|
| Characteristics | Low confidence | Medium confidence | High confidence | X ² | P value | |
| Anaesthetist | 7 | 6 | 10 | | | |
| Environmental health professional | 7 | 2 | 4 | | | |
| Gynaecologist | 4 | 3 | 4 | | | |
| Internist | 7 | 5 | 11 | | | |
| IESPS | 5 | 0 | 6 | | | |
| Surgeon | 5 | 2 | 10 | | | |
| Neurologist | 1 | 0 | 1 | | | |
| Ophthalmologist | 1 | 0 | 1 | | | |
| Dentist | 2 | 0 | 0 | | | |
| Radiologist | 2 | 0 | 1 | | | |
| Ophthalmic nurse | 1 | 0 | 3 | | | |
| Others‡ | 7 | 2 | 4 | | | |
| Attitude | | | | | | |
| Negative | 239 | 113 | 46 | 11.37 | 0.003 | |
| Positive | 122 | 72 | 28 | | | |
| | | | | | | |

Specialist=gynaecologist, internist, surgeon, neurologist, ophthalmologist, dentist, radiologist. Physician=general practitioner and any specialist doctors.

*Catholic, Jobha, etc.

†Health officer, midwife, laboratory professional, environmental health professional, pharmacist and dentist.

‡Biomedical Engineering, Emergency medicine, Nephrology , Cardiology and ENT specialists.

CDC, Center for Disease Control and Prevention; CSPH, comprehensive specialised hospital; HCWs, healthcare workers; IESPS, integrated emergency surgery professional specialty; PHEM, public health emergency epidemic disease management.



Figure 2 HCWs' confidence level in diagnosing and managing mpox disease in hospitals in Amhara Region, Northwest Ethiopia, 2022. HCWs, healthcare workers; HMPX, human mpox.

6

DIAGNOSIS AND MANAGEMENT OF MPOX

| 361 | 15 | 5 104 |
|-----------|-----------|----------------|
| 361 | 15 | 5 104 |
| 328 | 188 | 104 |
| 328 | 188 | 104 |
| 328 | 188 | 104 |
| 327 | 189 | 104 |
| 327 | 189 | 104 |
| 327 | 189 | 104 |
| 327 | 189 | 104 |
| 327 | 189 | 104 |
| 310 | 210 | 100 |
| 308 | 213 | 99 |
| 307 | 196 | 117 |
| 303 | 220 | 97 |
| 303 | 213 | 104 |
| 300 | 216 | 104 |
| 300 | 216 | 104 |
| 299 | 217 | 104 |
| 299 | 217 | 104 |
| 299 | 217 | 104 |
| 299 | 217 | 104 |
| 299 | 217 | 104 |
| 299 | 217 | 104 |
| 298 | 227 | 95 |
| 297 | 226 | 97 |
| 295 | 230 | 95 |
| 295 | 225 | 100 |
| 294 | 222 | 104 |
| 294 | 232 | 94 |
| 294 | 234 | 92 |
| 285 | 234 | 101 |
| 232 | 294 | 94 |
| 229 | 287 | 104 |
| 211 | 305 | 104 |
| 188 | 328 | 104 |
| ■ correct | Incorrect | ■ I don't know |
| | | |

mpox spreads by during pregnancy to the fetus, during or after I Pustules on the skin are the signs or symptoms of r Antibiotics are used to treat n paracetamol is one management option for mpox patie Symptomatic supportive care is to be considered in managemen mpox usually a self-limited disea Avoiding contact with objective by sick person can prevent sp Avoiding contact with a person that has a rash can prevent n Avoiding contact with sick animal can prevent spread of dis mpox is caused by a v mpox is spread from human to hur mpox is spread from animals to hun mpox is spread from humans to ani mpox is a bacterial disease infec mpox spreads from person-to-person by mouth-to-m rash of face. is one of the signs or symptoms of n swollen lymph nodes is signs or symptoms of n back pain and lower energy is signs /symptoms of n muscle aches is signs or symptoms of r headache is one of the signs or symptoms of n onset of symptoms is 6 to 13 days, but ranges 5 to 21 mpox and smallpox have similar signs and symp mpox occurs in primarily in tropical rainforest areas of Af Reporting symptoms of mpox is important to prevent m Fever is the common signs or symptoms of r Avoiding contact with wild animals prevent further n mpox spreads by mouth-to-skin contact (oral mpox spreads from person-to-person by skin-tompox can be treated with the available antiviral medicat Antibiotics are effective in mpox treat mpox spreads by face-to-face (such as talking, breathing mpox spreads by contaminated Environments to pe Vaccination is available to prevent a There is no treatment for mpox until

Frequent hands washing at least 20's with soap prevent 1

Figure 3 Healthcare workers' knowledge on questions related to the diagnosis, management, prevention and control of mpox disease in hospitals in Amhara Region, Northwest Ethiopia, 2022.

DISCUSSIONS

HCWs should be equipped with the required knowledge and confidence in clinically diagnosing and managing mpox disease in areas where there are scarce resources to install testing laboratories. However, this is a predominant challenge that the HCWs faced in the current mpox outbreak, which requires not only an intensive prevention strategy including vaccination but also early detection, quick response and proper management of affected patients. This study was designed to assess the HCWs' confidence level in diagnosing and managing mpox disease in hospitals in the Amhara Region. The findings of this study are important to design interventions that strengthen HCWs' preparedness for mitigation and responses towards the outbreak.⁵¹

The overall proportion of HCWs who had high confidence level in managing and diagnosing mpox disease was 31.5% (95% CI: 27.7%, 35.2%). Even though there were differences in the cut-off points in determining the outcome and the study participants, similar proportion (34.9%) was reported by a study conducted in Indonesia.⁵²

Similarly, the proportion of HCWs who had higher confidence level in managing the mpox disease was found to be 32.1% (95% CI: 28.2%, 35.7%). However, higher proportions (p=47.5%⁴⁶ and p=38.9%¹⁸) were reported in studies conducted in Kuwait and Jordan, respectively.

| Table 2 | Multivariable ordinal logistic regression of factors associate | d with HCWs' | confidence level in diagnosing and |
|----------|--|---------------|------------------------------------|
| managing | g mpox disease in hospitals in Amhara Region, Northwest E | thiopia, 2022 | |

| sits WHO, CDC and other we No | Low | | | | | P value |
|---|-------------------------------|-----------------------------|----------------------------|---|---|---------|
| sits WHO, CDC and other we No | | Medium | High | | | |
| No | bsites | | | | | |
| | 189 | 104 | 121 | 1 | 1 | |
| Yes | 70 | 62 | 74 | 261 | 1.596 (1.158, 2.198) | 0.004 |
| ccupational category | | | | | | |
| Nurse and others* | 209 | 137 | 132 | 1 | 1 | |
| Physician | 50 | 29 | 63 | 1.353 | 1.899 (1.318, 2.734) | 0.001 |
| ears of experience | | | | | | |
| <5 | 100 | 57 | 67 | 1 | 1 | |
| >5 | 159 | 109 | 128 | 0.212 | 1.297 (0.94, 1.789) | 0.113 |
| ospital where HCW works | | | | | | |
| Primary | 82 | 58 | 63 | 1 | 1 | |
| CSPH | 177 | 108 | 132 | 0.165 | 0.989 (0.714, 1.372) | 0.950 |
| ex | | | | | | |
| Female | 80 | 48 | 55 | 1 | 1 | |
| Male | 179 | 118 | 140 | 0.187 | 1.096 (0.783, 1.532) | 0.594 |
| articipates in morning essions | | | | | | |
| No | 142 | 74 | 96 | 1 | 1 | |
| Yes | 117 | 92 | 99 | 0.194 | 1.253 (0.925, 1.699) | 0.145 |
| HEM training | | | | | | |
| No | 215 | 135 | 117 | 1 | 1 | |
| Yes | 44 | 31 | 78 | 0.522 | 2.799 (1.942, 4.035) | 0.001 |
| ge of HCW | | | | | | |
| <30 years | 142 | 86 | 83 | 0.318 | 1 | |
| 30–35 years | 49 | 38 | 59 | 0.221 | 1.637 (1.118, 2.397) | 0.011 |
| >35 years | 68 | 42 | 53 | 1 | 1.202 (0.834, 1.731) | 0.322 |
| ttitude | | | | | | |
| Negative | 239 | 113 | 46 | 1 | 1 | |
| Positive | 122 | 72 | 28 | 0.277 | 1.724 (1.258, 2.362) | 0.001 |
| ut1 | | | | 0.274 | 0.860 (0.324, 1.396) | |
| ut2 | | | | 0.284 | 2.084 (1.527, 2.641) | |
| <30 years 30–35 years >35 years titude Negative Positive ut1 ut2 | 142 49 68 239 122 | 86 38 42 113 72 | 83 59 53 46 28 | 0.318 0.221 1 1 0.277 0.274 0.284 | 1 1.637 (1.118, 2.397) 1.202 (0.834, 1.731) 1 1 1.724 (1.258, 2.362) 0.860 (0.324, 1.396) 2.084 (1.527, 2.641) | |

Likewise, the proportion of HCWs who had higher confidence levels to diagnose the disease was also determined to be 35.0% (95% CI: 31.3%, 38.7%). Similar proportions were reported by studies conducted in Kuwait (32.3%) and Jordan (38.0%).1846

In this study, HCWs aged 30-35 years old had higher confidence level in diagnosing and managing mpox disease compared with HCWs aged less than 30 years old. This finding may be due to the fact that HCWs in this age range capitalised on their knowledge and prior clinical experiences such as with the COVID-19 pandemic to

and updates about emerging and re-emerging epidemics. This study also found that those HCWs with positive attitude had higher confidence in diagnosing and managing mpox disease compared with those HCWs with negative attitude. This may be because having a positive attitude towards understanding mpox helps HCWs thrive in searching for new information regarding the diagnosis and management of the disease. The information-seeking behaviour might help the HCWs to develop a higher level of confidence towards the management and diagnosis of the disease. This finding was also supported by the current study, which revealed that HCWs who had visited different websites such as the WHO and CDC websites had higher odds of having a high level of confidence in diagnosing and managing mpox disease compared with those who had not. The mere reason behind this might be due to the fact that the WHO and other partners like CDC might release accurate and updated information on a daily basis regarding the signs and symptoms, transmission, prevention and treatment of the virus and the global strategies for the prevention and control of mpox outbreaks.⁵³ The importance of prior information about the mpox virus was mentioned to be an independent predictor of a higher level of confidence among GPs as those GPs who had received information on mpox virus during their medical education had higher confidence than those who had never received such information.⁵⁴ Therefore, visiting different websites could improve HCWs' knowledge and attitude about mpox, leading to a high level of confidence in the diagnosis and management of re-emerging viruses.

Like another study conducted in Jordan,¹⁸ this study identified that physicians (GPs and specialists) had a higher confidence level in diagnosing and managing mpox disease compared with nurses and other professionals. The possible explanation might be due to the fact that physicians have higher and intensive educational exposure during their medical education, which might help them understand the fundamental sciences of communicable diseases like mpox virus. In addition, the physicians might have an opportunity to attend regional and international conferences during such type of pandemics, which update them of the current worldwide understanding about the diseases. This was explained by a study conducted in Indonesia, which suggested that attending national conferences (at least one) equips GPs with better confidence.⁵² Another possible reason might be because physicians such as specialists have practical experiences in the management and diagnosis of similar pandemics such as COVID-19, which help them to be sensitive to potentially threatening mpox virus epidemics across the globe. In contrast to our finding and this justification, a study conducted in Kuwait⁴⁶ reported that nurses displayed higher self-reported confidence levels to diagnose and manage the disease. The possible reason might be the differences in the variable categorisation: this study categorised the variable into dichotomous variable (GPs and specialists vs nurse and other professionals); however, the latter study categorised the variable into four categories.

Those HCWs who had received training in public health epidemic-prone diseases had higher confidence levels in diagnosing and managing mpox disease. Previous studies conducted in Indonesia,⁵² Australia⁵⁵ and Italy⁵⁶ agreed with our findings that receiving information during medical training was significantly associated with having good knowledge about mpox, which increases HCWs'

confidence level. HCWs' confidence level increased with prolonged education and training in healthcare centres,⁵⁵ as adequate training and continuing medical education are important to ensure the build-up of confidence in diagnosing and managing infectious diseases.⁵⁷

Conclusions

The overall HCWs' confidence level in diagnosing and managing mpox disease in the Amhara Region was low compared with what was recommended by the WHO. The modifiable variables such as positive attitude, professional category (being a GP and specialist doctor), age, and visiting the WHO. CDC and other amenable websites and visiting the WHO, CDC and other amenable websites were found to be significantly associated with HCWs' higher confidence level in diagnosing and managing g mpox disease. Raising awareness and confidence levels of HCWs in diagnosing and managing mpox disease can strengthen their preparedness for the mitigation and response for the emerging threat of mpox. For instance, training in the WHO's rapid interim guideline for the clinical management and infection prevention and control of B mpox should be given for all HCWs in the study area.⁵⁸ Additionally, those physicians with higher confidence levels in diagnosing and managing diseases should share their knowledge and skills with nurses and other health professionals.

Author affiliations

¹Department of Environmental Health, Injibara University, Injibara, Amhara, Ethiopia
 ²Department of Public Health, Injibara University, Injibara, Amhara, Ethiopia
 ³Department of Epidemology, Bichena Hospital, Injibara, Amhara, Ethiopia
 ⁴Department of Public Health, West Gojjam Zone, Finoteselam, Amhara, Ethiopia
 ⁵Department of Public Health, Dangila Primary Hospital, Dangila, Amhara, Ethiopia
 ⁶Department of Public Health, Dejen Primary Hospital, Dejen, Amhara, Ethiopia
 ⁷Department of Environmental Health Sciences, Public Health, Debre Tabor University, Debre Tabor, Ethiopia

Contributors AGY conceptualised and designed the study, acquired or analysed and interpreted the data, and wrote the manuscript. AT designed the study, and analysed, interpreted and wrote the manuscript. GM conceived the study and reviewed and wrote the manuscript. TDT reviewed and wrote the manuscript. AM reviewed and wrote the manuscript,. HT reviewed and wrote the manuscript. AA reviewed and wrote the manuscript. EM edited the manuscript. AS edited the manuscript. DT edited the manuscript. EM edited the manuscript. CY designed the study, acquired the data, analysed and interpreted the data, and wrote the manuscript. All authors were responsible for the overall content of the manuscript and for conducting the study.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Map disclaimer The inclusion of any map (including the depiction of any boundaries therein), or of any geographic or locational reference, does not imply the expression of any opinion whatsoever on the part of BMJ concerning the legal status of any country, territory, jurisdiction or area or of its authorities. Any such expression remains solely that of the relevant source and is not endorsed by BMJ. Maps are provided without any warranty of any kind, either express or implied.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants and ethical approval was obtained from the Institutional Review Board (IRB) (no. /RCS/70024/26) of the Debre Tabor University, College of Medicine and Health Sciences. Before data collection,

Open access

BMJ Open: first published as 10.1136/bmjopen-2023-080791 on 5 July 2024. Downloaded from http://bmjopen.bmj.com/ on June 12, 2025 at Agence Bibliographique de l Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

formal permission letters were obtained from each hospital. Similarly, facility heads were communicated through supporting letters and informed about the purpose of the study before actual data collection. Informed verbal consent was obtained from the HCWs. The respondents were also informed that they have the full right to withdraw or refuse at any time during interviews. Data confidentiality was maintained by avoiding possible identifiers, such as changing the names of study participants into ID numbers.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Almaw Genet Yeshiwas http://orcid.org/0000-0002-1803-5450 Tilahun Degu Tsega http://orcid.org/0000-0002-2388-3171 Hiwot Tesfa http://orcid.org/0000-0003-2533-339X

REFERENCES

- 1 Karagoz A, Tombuloglu H, Alsaeed M, et al. Monkeypox (Mpox) virus: classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health 2023;16:531–41.
- 2 Hirani R, Noruzi K, Iqbal A, *et al.* A review of the past, present, and future of the Monkeypox virus: challenges, opportunities, and lessons from COVID-19 for global health security. *Microorganisms* 2023;11:2713.
- 3 Perramon A. Analysis of the Epidemiological dynamic of Monkeypox from 15th may to 31st August 2022. 2022;160. Available: www.enfe rmedadesemergentes.com
- 4 Ilic I, Zivanovic Macuzic I, Ilic M. Global outbreak of human Monkeypox in 2022: update of epidemiology. *Trop Med Infect Dis* 2022;7:264.
- 5 Galassi FM, Sineo L, Papa V, *et al*. Monkeypox between Dermatology and anthropology: A model for evolutionary medicine. *Clin Dermatol* 2023;41:423–4.
- 6 Xiang Y, White A. Monkeypox virus emerges from the shadow of its more infamous cousin: family biology matters. *Emerg Microbes Infect* 2022;11:1768–77.
- 7 Cheema AY, Ogedegbe OJ, Munir M, et al. Monkeypox: A review of clinical features, diagnosis, and treatment. Cureus 2022;14:e26756.
- 8 Ladnyj ID, Ziegler P, Kima E. A human infection caused by Monkeypox virus in Basankusu territory, democratic Republic of the Congo. *Bull World Health Organ* 1972;46:593:593–7:.
- 9 Antunes F, Cordeiro R, Virgolino A. Monkeypox: from A neglected tropical disease to a public health threat. *Infect Dis Rep* 2022;14:772–83.
- 10 Mande G, Akonda I, De Weggheleire A, et al. Enhanced surveillance of Monkeypox in bas-Uélé, democratic Republic of Congo: the limitations of symptom-based case definitions. Int J Infect Dis 2022;122:647–55.
- 11 Kraemer MUG, Tegally H, Pigott DM, et al. Tracking the 2022 Monkeypox outbreak with Epidemiological data in real-time. Lancet Infect Dis 2022;22:941–2.
- 12 Update E. Monkeypox multi-country outbreak. European Centre for Disease Prevention and Control 2022.
- 13 WHO. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends, 2023. Available: https://worldhealthorg.shinyapps.io/mpx_global
- 14 CDC. 2022-2023 Mpox Outbreak Global Map, 2023. Available: https://www.cdc.gov/poxvirus/mpox/response/2022/world-map.html

- 15 Ilic I, Ilic M. Historical review: towards the 50th anniversary of the last major smallpox outbreak (Yugoslavia, 1972). *Travel Med Infect Dis* 2022;48:S1477-8939(22)00073-4.
- 16 Yousaf M, Ismail S, Ullah A, et al. Immuno-Informatics profiling of Monkeypox virus cell surface binding protein for designing a next generation multi-Valent peptide-based vaccine. *Front Immunol* 2022;13:1035924.
- 17 Titanji BK, Tegomoh B, Nematollahi S, et al. Monkeypox: a contemporary review for healthcare professionals. Open Forum Infect Dis 2022;9:ofac310.
- 18 Sallam M, Al-Mahzoum K, Al-Tammemi AB, *et al.* Assessing Healthcare workers' knowledge and their confidence in the diagnosis and management of human Monkeypox: A crosssectional study in a middle Eastern country. *Healthcare* 2022;10:1722.
- 19 Tarín-Vicente EJ, Alemany A, Agud-Dios M, et al. Clinical presentation and virological assessment of confirmed human Monkeypox virus cases in Spain: a prospective observational cohort study. The Lancet 2022;400:661–9.
- 20 Morgan CN, Whitehill F, Doty JB, et al. Environmental persistence of Monkeypox virus on surfaces in household of person with travelassociated infection. Emerg Infect Dis 2022;28:1982–9.
- 21 Peiró-Mestres A, Fuertes I, Camprubí-Ferrer D, et al. Frequent detection of Monkeypox virus DNA in saliva, semen, and other clinical samples from 12 patients. *Euro Surveill* 2022;27:2200503.
- 22 Vaughan A, Aarons E, Astbury J, *et al*. Human-to-human transmission of Monkeypox virus, United kingdom, October 2018. *Emerg Infect Dis* 2020;26:782–5.
- 23 Al-Tammemi AB, Albakri R, Alabsi S. The outbreak of human Monkeypox in 2022: A changing epidemiology or an impending Aftereffect of smallpox eradication. *Front Trop Dis* 2022;3:951380.
- 24 Mbala PK, Huggins JW, Riu-Rovira T, et al. Maternal and fetal outcomes among pregnant women with human Monkeypox infection in the Democratic Republic of Congo. J Infect Dis 2017;216:824–8.
- 25 Rodriguez-Morales AJ, Lopardo G. Monkeypox: another sexually transmitted infection *Pathogens* 2022;11:713.
- 26 Bunge EM, Hoet B, Chen L, et al. The changing epidemiology of human Monkeypox – A potential threat? A systematic Review PLOS neglected tropical diseases. PLoS Negl Trop Dis 2022;16:e0010141.
- 27 Simpson K, Heymann D, Brown CS, et al. Human Monkeypox–after 40 years, an unintended consequence of smallpox eradication. Vaccine 2020;38:5077–81.
- 28 Weinstein RA, Nalca A, Rimoin AW, et al. Reemergence of Monkeypox: prevalence, diagnostics, and countermeasures. Clin Infect Dis 2005;41:1765–71.
- 29 Beer EM, Rao VB. A systematic review of the epidemiology of human Monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* 2019;13:e0007791.
- 30 Rimoin AW, Mulembakani PM, Johnston SC, et al. Major increase in human Monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. Proc Natl Acad Sci USA 2010;107:16262–7.
- 31 Petersen BW, Kabamba J, McCollum AM, et al. Vaccinating against Monkeypox in the Democratic Republic of the Congo. Antiviral Res 2019;162:171–7.
- 32 Khodakevich L, Szczeniowski MNambu-ma-Disuet al. Monkeypox virus in relation to the ecological features surrounding human settlements in Bumba zone, Zaire. Trop Geogr Med 1987;39:56–63.
- 33 Haider N, Guitian J, Simons D, et al. Increased outbreaks of Monkeypox highlight gaps in actual disease burden in sub-Saharan Africa and in animal reservoirs. Int J Infect Dis 2022;122:107–11.
- Ortiz-Martínez Y, Galvis-Cataño LM, Arias-Rodríguez D, et al. Youtube and 2022 Monkeypox outbreak: opportunities for awareness and infection control. J Hosp Infect 2022.:S0195-6701(22)00226-2.
 Assessment BB. Monkeypox multi-country outbreak. 2022
- 35 Assessment RR. Monkeypox multi-country outbreak. 2022.
 36 Sah R, Mohanty A, Hada V, *et al.* The emergence of Monkeypox: A global health threat. *Cureus* 2022;14:e29304.
- 37 Al-Musa A, Chou J, LaBere B. The resurgence of a neglected Orthopoxvirus: immunologic and clinical aspects of Monkeypox virus infections over the past six decades. *Clin Immunol* 2022;243:S1521-6616(22)00189-9.
- 38 mondiale de la Santé, O. and W.H. Organization. Epidemiology of human Monkeypox (Mpox)–Worldwide, 2018–2021–Épidémiologie de la Variole Simienne Chez L'Humain–Dans le Monde, 2018-2021. Weekly Epidemiological Record= Relevé Épidémiologique Hebdomadaire 2023;98:29–36.
- 39 Antunes F, Virgolino A. Monkeypox mysteries of the new outbreak in non-Endemic areas. Int J Environ Res Public Health 2022;19:14881.
- 40 Shariq A, Rasheed Z, Abdulmonem WA. Human Monkeypox: an update on knowledge and future implications. *Int J Health Sci* (*Qassim*) 2022;16:1–2.

- 41 Koenig KL, Beÿ CK, Marty AM. Monkeypox 2022: a primer and identify-isolate-inform (3I) tool for emergency medical services professionals. *Prehosp Disaster Med* 2022;37:687–92.
- 42 Taherdoost H. Determining sample size; how to calculate survey sample size. Int J Econom Manag Syst 2017.
- 43 Sallam M, Al-Mahzoum K, Dardas LA, et al. Knowledge of human Monkeypox and its relation to conspiracy beliefs among students in Jordanian health schools: filling the knowledge gap on emerging Zoonotic viruses. *Medicina* 2022;58:924.
- 44 Ramli N, Rahman NAA, Haque M, et al. Knowledge, attitude, and practice regarding osteoporosis among Allied health sciences students in a public University in Malaysia. *Erciyes Med J* 2018;40:210–7.
- 45 Rony MKK, Sharmi PD, Akter D, et al. Knowledge and attitude regarding human Monkeypox virus infection among nurses: A crosssectional study. SAGE Open Nursing 2023;9:23779608231216619.
- 46 Alsanafi M, Al-Mahzoum K, Sallam M. Monkeypox knowledge and confidence in diagnosis and management with evaluation of emerging virus infection conspiracies among health professionals in Kuwait. *Pathogens* 2022;11:994.
- 47 Alshahrani NZ, Alzahrani F, Alarifi AM, et al. Assessment of knowledge of Monkeypox viral infection among the general population in Saudi Arabia. *Pathogens* 2022;11:904.
- 48 Hasan S, Saeed S. Monkeypox disease: an emerging public health concern in the shadow of COVID-19 pandemic: an update. *Trop Med Infect Dis* 2022;7:283.
- 49 Hong J, Pan B, Jiang H-J, et al. The willingness of Chinese Healthcare workers to receive Monkeypox vaccine and its independent predictors: A Cross-Sectional survey. J Med Virol 2023;95:e28294.

- 50 Huang Y, Mu L, Wang W. Monkeypox: epidemiology, pathogenesis, treatment and prevention. *Signal Transduct Target Ther* 2022;7:373.
- 51 Wenham C, Eccleston-Turner M. Monkeypox as a PHEIC: implications for global health governance. *The Lancet* 2022;400:2169–71.
- 52 Harapan H, Setiawan AM, Yufika A, *et al.* Confidence in managing human Monkeypox cases in Asia: A cross-sectional survey among general practitioners in Indonesia. *Acta Tropica* 2020;206:S0001-706X(20)30005-X.
- 53 World Health Organization. Obesity: preventing and managing the global epidemic. 2000.
- 54 Harapan H, Wagner AL, Yufika A, et al. Acceptance and willingness to pay for a hypothetical vaccine against Monkeypox viral infection among frontline physicians: A cross-sectional study in Indonesia. Vaccine 2020;38:6800–6.
- 55 McNair R, Griffiths L, Reid K, *et al.* Medical students developing confidence and patient Centredness in diverse clinical settings: a longitudinal survey study. *BMC Med Educ* 2016;16:176.
- 56 Gallè F, Bianco L, Da Molin G, et al. Monkeypox: what do you know about that?" Italian adults' awareness of a new epidemic. Pathogens 2022;11:1285.
- 57 Choudhry NK, Fletcher RH, Soumerai SB. Systematic review: the relationship between clinical experience and quality of health care. *Ann Intern Med* 2005;142:260–73.
- 58 WHO. Clinical management and infection prevention and control guideline, 2022. Available: https://iris.who.int/bitstream/handle/ 10665/355798/WHO-MPX-Clinical_and_IPC-2022.1-eng.pdf? sequence=1